European Corona Vaccine Trial Accelerator Platform

Funding programme: Horizon 2020 (N 101037867)


Budget: €12M

Duration: 3 years (Jan 2021 - Dec 2023)

VACCELERATE will accelerate phase 2 & 3 COVID-19 vaccine trials. VACCELERATE brings together the different stakeholders involved in vaccine development across the continent to develop a platform for trial design and conduct.

VACCELERATE will include capacity mapping to identify suitable sites as well as capacity building through the creation of dedicated training. Volunteer registries and access to laboratory sites are also provided within the framework of the project. The project will also ensure the harmonisation of data collection, open data sharing and pooling of data for more robust analysis and data standardisation.

The network once developed for the COVID-19 pandemic can then serve to address new emerging infectious diseases and play a pivotal role in the vaccine development capacities of Europe.

Ecrin's role in VACCELERATE

ECRIN is providing trial management services (WP11 (EU-COVAT-1 AGED, WP12 (EU-COVAT-2 BOOSTAVAC) for the multinational expansion of the vaccine platform trials within the VACCELERATE project.  ECRIN leads VACCELERATE WP9 “Data Management, Standards and Sharing” and thereby playing a vital role for promoting, sharing, interoperability and the FAIRness of the data generated within the VACCELERATE project. In WP7 (Public Health Needs) ECRIN is involved in development of the phase 2 & 3 master protocol templates for the platforms trials. ECRIN developed capacity development through the development of training (WP5).